Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Prices $2.5 Million Share Offering and Issues Warrants Up to $4.6 Million

Negative Impact 3 of 5 financing Written later

Acurx Pharmaceuticals agreed on April 15, 2026 to sell about $2.5 million of common stock and pre-funded warrants in a registered direct offering at $3.03 per share, before placement agent fees and expenses. A concurrent private placement adds Series H warrants for 1,650,170 shares at $2.78 per share, which could bring up to about $4.6 million if fully exercised, so existing shareholders face dilution and the warrants are not assured to be exercised.

Key points

  • Registered offering: 816,068 common shares at $3.03 per share, plus pre-funded warrants for 9,017 shares at $3.029, for about $2.5 million gross before fees
  • Concurrent private placement: Series H warrants for 1,650,170 shares at $2.78 per share, exercisable immediately and expiring 24 months after the resale registration becomes effective
  • Placement agent H.C. Wainwright & Co. receives a cash fee of 6.0% of gross proceeds, plus up to $50,000 for legal fees and $15,950 for clearing expenses
  • Closing is expected on or about April 16, 2026; the company plans to use proceeds for working capital and general corporate purposes

The filing

CompanyAcurx Pharmaceuticals, Inc. (ACXP)
Form8-K, current report
Filed with the SECApr 16, 2026, 8:14 AM ET
Accession number0001104659-26-044093

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.